Some great insights there and statistically significant findings more importantly.
Skin grafts were applied to 39 patients (84.8%) treated with CCS compared with 28 (54.9%) treated with BTM (P =.006); the remaining wounds healing secondarily.
The rate of skin graft failure was significantly higher in the CCS cohort (n = 9 [23.1%]) compared with the BTM group (n = 1 [3.6%]) (P =.006).
More secondary procedures were required after CCS placement (mean ± standard deviation, 1.9 ± 1.8; range, 0-9) than after BTM (mean, 1.0 ± 0.9; range 0-4) (P =.002).
Less rates of skin grafting required, extremely lower rates of graft failure and less secondary procedures required (P<0.05). This is what you want to see when calculating health economics of a medical device! Cheers for the insights KJC.
- Forums
- ASX - By Stock
- The Clinicians Speak
Some great insights there and statistically significant findings...
-
- There are more pages in this discussion • 868 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.34 |
Change
-0.040(1.68%) |
Mkt cap ! $1.615B |
Open | High | Low | Value | Volume |
$2.43 | $2.43 | $2.33 | $1.728M | 733.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4407 | $2.33 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.34 | 16721 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2602 | 2.330 |
8 | 15948 | 2.320 |
5 | 19030 | 2.310 |
9 | 23525 | 2.300 |
5 | 13953 | 2.290 |
Price($) | Vol. | No. |
---|---|---|
2.340 | 16721 | 2 |
2.350 | 9130 | 4 |
2.360 | 7740 | 2 |
2.370 | 7740 | 2 |
2.380 | 2602 | 1 |
Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |